Abeona Therapeutics Inc (NASDAQ:ABEO) Stock Position Decreased by Barclays PLC

Barclays PLC cut its stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) by 28.0% during the third quarter, Holdings Channel reports. The firm owned 55,000 shares of the biopharmaceutical company’s stock after selling 21,394 shares during the quarter. Barclays PLC’s holdings in Abeona Therapeutics were worth $348,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Jane Street Group LLC acquired a new stake in Abeona Therapeutics during the 3rd quarter worth about $84,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Abeona Therapeutics in the third quarter worth approximately $151,000. XTX Topco Ltd purchased a new position in shares of Abeona Therapeutics in the third quarter worth approximately $160,000. Bank of New York Mellon Corp raised its holdings in shares of Abeona Therapeutics by 2.0% during the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock valued at $515,000 after acquiring an additional 2,434 shares during the period. Finally, GSA Capital Partners LLP lifted its position in shares of Abeona Therapeutics by 54.3% in the 3rd quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock valued at $607,000 after acquiring an additional 33,831 shares in the last quarter. 80.56% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ABEO has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research report on Monday, November 25th. Cantor Fitzgerald reiterated an “overweight” rating and set a $18.00 price target on shares of Abeona Therapeutics in a report on Tuesday, October 29th. Finally, StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, December 31st.

Abeona Therapeutics Trading Up 1.9 %

Abeona Therapeutics stock opened at $6.02 on Friday. Abeona Therapeutics Inc has a 12 month low of $3.05 and a 12 month high of $9.01. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The stock has a market cap of $261.70 million, a P/E ratio of -2.24 and a beta of 1.46. The company’s fifty day simple moving average is $6.00 and its 200-day simple moving average is $5.61.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.